Over the past 10 years, several new treatment strategies have
been developed and many new agents have been evaluated for the
treatment of metastatic breast cancer . Some of these agents
represent analogs of previously existing drugs, whereas others
belong to new molecular families. Some agents have novel mechanisms
of action, different from those of drugs used in the past. Several
agents have been approved by the regulatory agencies for the treatment
of breast cancer; others are still completing clinical evaluation,
and many more are in preclinical evaluation. In this article,
I will review agents with demonstrated efficacy against breast
cancer (Table 1).
Amonafide (benzisoquinolinedione, nafidimide) is a synthetic compound
with potent antiviral and cytotoxic activity. It acts as a DNA-intercalating
agent and is an inhibitor of topoisomerase II . Phase I trials
using 3 different schedules were conducted: daily ´ 5 every
3 weeks, bolus infusion every 3 to 4 weeks, and 24-hour continuous
infusion every 4 weeks. The dose-limiting toxicity was reversible
myelosuppression. Nonhematologic toxicity was mild, consisting
mostly of nausea and vomiting, which was easily controlled with
antiemetics. The daily ´ 5 schedule of administration was
recommended for phase II trials. The recommended phase II dosage
was 300 mg/m² daily for 5 consecutive days. The daily dose
was administered over 1 hour. Amonafide has modest antitumor activity
against prostate and small-cell lung cancer. Three phase II trials
performed in patients with breast cancer have been reported [3-5].
The overall activity of the drug was modest, between 15% and 20%.
Two complete remissions were observed among 103 patients. The
response rate was modest, even in patients who had undergone no
Amonafide is acetylated to N-acetyl- amonafide [6,7]. Because
of the known, marked individual variation in plasma concentration
of N-acetyl-amonafide, an acetylator phenotype was determined
in a small group of patients. Fast acetylators were found to have
a much higher overall response rate (3 of 8; 38%) than slow acetylators
(1 of 16; 6%).5 An acetylator phenotype also correlated with toxicity,
suggesting that the recommended phase II dose was too high for
fast acetylators and too low for slow acetylators (Table 2). Additional
trials are indicated for this agent to confirm this latter observation,
which suggests that in a subgroup of patients with breast cancer,
amonafide has marked antitumor activity. Dosing based on an acetylator
phenotype is being tested prospectively to improve the therapeutic
ratio of this agent. Because extramedullary toxicity is modest,
additional dose-escalation studies, perhaps with hematopoietic
growth factor support, would be indicated to assess the full range
of doses with this agent.
Anthracyclines are the most active single agents in the treatment
of breast cancer, but their clinical usefulness is limited by
cardiotoxicity related tocumulativedos.Epirubicin is a potentially
less cardiotoxic doxorubicin analog, but it has not been approved
by the Food and Drug Administration (FDA) because of insufficient
supportive evidence. Several new anthracycline derivatives have
entered clinical trials, and a few of them have been evaluated
against metastatic breast cancer .
Theprubicin underwent phase II evaluation in the 1980s;
several trials suggested activity equivalent to that of doxorubicin
[9,10]. Limited phase II trials of theprubicin in combination
therapy suggested no difference in activity between theprubicin-
and doxorubicin-containing combinations . However, no direct
comparative trials have been reported.
Liposomal Doxorubicin (TLC D-99)--A new approach to reduce
the toxicity of anticancer drugs is to encapsulate otherwise soluble
drugs into multilamellar lipid particles (liposomes). Doxorubicin
is the single most studied anticancer drug encapsulated in liposomes.
TLC D-99 was developed with the intent of reducing the cardiotoxicity
of doxorubicin. Phase I trials determined that an intermittent
3-weekly schedule was appropriate, and the maximum tolerated dose
was found to be between 60 and 90 mg/m². Activity was similar
to that of other anthracyclines in limited phase II studies .
In combination with standard agents, liposomal doxorubicin achieved
efficacy similar to that of standard anthracycline-containing
regimens . To date, results suggest that higher cumulative
doses can be administered with a lower incidence of and less severe
cardiotoxicity than those of the soluble free agent. However,
comparative trials to determine the relative efficacy and safety
of this agent are just completing accrual. Other liposome-encapsulated
anthracyclines are entering phase I/II studies, but the results
of such studies have not yet been published.
The anthracenediones (mitoxantrone [Novantrone], bisantrene, and
others) were developed to reduce the frequency and severity of
anthracycline-induced cardiotoxicity . Although mitoxantrone
is less cardiotoxic than the anthracyclines, it is also somewhat
less effective. For this reason, mitoxantrone has not received
FDA approval for treatment of breast cancer. The anthrapyrazoles
are structurally similar to mitoxantrone . They maintain the
planar conformation and cationic nature of the anthracyclines,
essential for DNA intercalation. Several anthrapyrazoles have
Losoxantrone (CI-941)--Preclinical evaluation demonstrated
that losoxantrone induced both single- and double-stranded breaks
in DNA and was a potent inhibitor of DNA synthesis . In preclinical
models, it was less cardiotoxic than doxorubicin . Phase I
clinical trials demonstrated that when losoxantrone was administered
in an intermittent single-dose schedule, the maximum tolerated
dose was 55 mg/m², and the dose-limiting toxicities were
leukopenia and neutropenia .
At least two phase II studies of losoxantrone have been reported
[19,20]; both included previously untreated and previously treated
patients with metastatic breast cancer. The objective response
rates obtained in these studies are shown in Table 3. A few complete
remissions were observed, and response durations in these trials
compared favorably with those expected after standard combination
chemotherapy. Toxicity consisted mostly of leukopenia, although
up to 40% of patients were reported to have alopecia. Acute toxicity
was negligible. However, a recent update reported that 3% of patients
developed congestive heart failure . Therefore, this agent
is as active as or more active than existing anthracyclines; however,
the drug is not devoid of cardiotoxicity.
Teloxantrone (CI-937)--This second anthrapyrazole has also
completed phase I/II clinical trials [22,23]. At least one phase
II study in breast cancer has been reported in abstract form .
At an early stage of follow-up, there were major objective responses
in 9 of 47 patients, and a minor response was achieved in another
11% (Table 3). No additional information is available about this
trial. The pattern, frequency, and severity of toxicity appeared
to be similar to those of losoxantrone.
Piroxantrone--Piroxantrone hydrochloride (oxantrazole,
NSC-349174) is the third anthrapyrazole compound currently undergoing
testing in clinical trials . No reports of its activity in
breast cancer are available at this time.
Topoisomerases are recognized targets for anticancer agents. Topoisomerase
I makes a single cut in the DNA duplex and relieves transcription-associated
torsional strain. Camptothecin, a plant alkaloid with broad-spectrum
activity and a novel mechanism of action, was isolated from Camptotheca
acuminata more than 2 decades ago. In the early 1970s, phase
I clinical trials showed marked hematologic and nonhematologic
toxicity, including severe cystitis; this led to the conclusion
that the compound was too toxic for clinical development. More
recently, several novel semisynthetic and synthetic analogs designed
to be less toxic and to overcome the problems associated with
pharmaceutical formulations of natural products have appeared.
These analogs are completing clinical development. The parent
compound and the recently developed analogs inhibit both DNA and
RNA synthesis by topoisomerase I-mediated effects . The analogs
of interest in the area of breast cancer research and treatment
include topotecan, irinotecan, and probably SN-38. The relative
efficacy and toxicity of the camptothecin analogs were evaluated
in preclinical models .
Topotecan--Topotecan is a potent, water-soluble camptothecin
analog with a broad spectrum of antitumor activity, including
human colorectal, non-small- cell lung, ovarian, breast, and renal
cell carcinomas .
In phase II trials, topotecan was administered at a dosage of
1.5 mg/m² daily for 5 consecutive days to patients with metastatic
breast cancer who had received minimal or no prior chemotherapy
treatment. Cycles of treatment were repeated every 3 weeks .
Sixteen patients had been treated at the time of the report, 14
of whom were evaluable. Five patients achieved a partial response
(36%), and 1 patient achieved a minor response. Three patients
had stable disease, with the remaining five patients showing progression
of metastatic disease. Myelosuppression, especially granulocytopenia,
was observed. Mild fatigue, mild to moderate alopecia, and skin
rashes were also reported.
Irinotecan (CPT-11) is another water-soluble camptothecin
analog. Although it also is a topoisomerase I inhibitor, unlike
camptothecin and topotecan, CPT-11 has limited antitumor activity
in vitro. In vivo, it is converted to 7-ethyl-10-hydroxy-camptothecin
(SN-38), a metabolite with a 100-fold greater antitumor activity
than CPT-11 in vitro. This agent has antitumor activity against
small-cell and non-small-cell lung cancer, gynecologic and gastrointestinal
tumors, and leukemia and lymphoma. Until recently, severe side
effects, such as leukopenia and diarrhea, had limited its clinical
In a recently reported phase II trial, irinotecan was administered
to patients with metastatic breast cancer who had undergone minimal
or no prior chemotherapy . The agent was administered intravenously
over 30 minutes at a dosage of 350 mg/m² every 3 weeks. Of
29 patients treated, 21 were evaluable at the time of the report;
these patients had a good performance status and a moderate amount
of tumor burden. Twelve patients were evaluable for response.
One achieved a complete remission, whereas four others ex- perienced
no change. The remaining seven patients had progressive disease.
Grade II or higher nausea and vomiting, diarrhea, abdominal cramps,
alopecia, neutropenia, asthenia, and hot flashes were reported.
Three patients were removed from the study because of toxicity.
In a second study, reported in abstract form only, 15 (23%) of
65 patients responded to irinotecan treatment . No information
is available about the duration of treatment or the effect of
camptothecin analogs on quality of life.
1. Hortobagyi GN: Overview of new treatments for breast cancer.
Breast Cancer Res Treat 21:3-13, 1992.
2. Saez R, Craig JB, Kuhn JG, et al: Phase I clinical investigation
of amonafide. J Clin Oncol 7:1351-1358, 1989.
3. Scheithauer W, Dittrich C, Kornek G, et al: Phase II study
of amonafide in advanced breast cancer. Breast Cancer Res Treat
4. Costanza ME, Berry D, Henderson IC, et al: Amonafide: An active
agent in the treatment of previously untreated advanced breast
cancer: A Cancer and Leukemia Group B Study (CALGB 8642). Clin
Cancer Res 1:699-704, 1995.
5. Ratain MJ, Mick R, Berezin F, et al: Phase I study of amonafide
dosing based on acetylator phenotype. Cancer Res 53:2304-2308,
6. Ratain MJ, Mick R, Berezin F, et al: Prospective correlation
of acetylator phenotype with amonafide toxicity. Proc Am Soc Clin
Oncol 10:101, 1991. Abstract.
7. Ratain MJ: Pharmacogenetics of amonafide: An active drug in
breast cancer? Cancer Invest 12:38, 1994. Abstract.
8. Booser DJ, Hortobagyi GN: Anthracycline antibiotics in cancer
therapy. Drugs 47:223-258, 1994.
9. Samonigg H, Kasparek AK, Stöger H, et al: 4'-O-Tetrahydropyranyl-doxorubicin
in advanced breast cancer: A phase II study. Cancer Chemother
Pharmacol 26:293-296, 1990.
10. Enomoto K, Abe O, Tominaga T, et al: Clinical study of pirarubicin
for breast cancer in Japan. Am J Clin Oncol 13:S48-S53, 1990.
11. Dhingra K, Fry DW, Newman RA, et al: Phase II clinical and
pharmacological study of pirarubicin in combination with 5-fluorouracil
and cyclophosphamide in metastatic breast cancer. Clin Cancer
Res 1:691-697, 1995.
12. Batist G, Saletan S, Panasci L, et al: High response rate
and visceral organ targeting by liposomal doxorubicin (TLC D-99)
in metastatic breast cancer. Breast Cancer Res Treat 23:132, 1992.
13. Fonseca GA, Valero V, Buzdar A, et al: Phase II study of TLC
D-99 (liposomal doxorubicin) in patients with metastatic breast
carcinoma. Proc Am Soc Clin Oncol 14:99, 1995. Abstract.
14. Shenkenberg TD, von Hoff DD: Mitoxantrone: A new anticancer
drug with significant clinical activity. Ann Intern Med 105:67-81,
15. Showalter HDH, Fry DW, Leopold WR, et al: Design, biochemical
pharmacology, electrochemistry, and tumor biology of antitumor
anthrapyrazoles. Anticancer Drug Des 1:73-85, 1986.
16. Fry DW, Boritzki TJ, Besserer JA, et al: In vitro DNA strand
scission and inhibition of nucleic acid synthesis in L1210 leukemia
cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazole-6(2H)-ones
(anthrapyrazoles). Biochem Pharmacol 34:3499-3508, 1985.
17. Fagan MA, Hacker MP, Newman RA: Cardiotoxic potential of substituted
anthra[1,9-cd]pyrazole-6(2H)-ones (anthrapyrazoles) as assessed
by the fetal mouse heart organ culture. Proc Am Assoc Cancer Res
25:302, 1984. Abstract.
18. Foster BJ, Graham MA, Newell DR, et al: Phase I study of the
anthrapyrazole CI-941 with pharmacokinetically guided dose escalation.
Proc Am Soc Clin Oncol 7:64, 1988. Abstract.
19. Talbot DC, Smith IE, Mansi JL, et al: Anthrapyrazole CI-941:
A highly active new agent in the treatment of advanced breast
cancer. J Clin Oncol 9:2141-2147, 1991.
20. ten Bokkel Huinink W, Moore M, Smith I, et al: A phase II
study of losoxantrone (DuP 941) in advanced breast cancer. Eur
J Cancer 29A:S78, 1993. Abstract.
21. Calvert H, Smith I, Jones A, et al: Phase II study of losoxantrone
in previously treated and untreated patients with advanced breast
cancer. Proc Am Soc Clin Oncol 13:71, 1994. Abstract.
22. Erlichman C, Moore M, Kerr IG, et al: Phase I pharmacokinetic
and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
Cancer Res 51:6317-6322, 1991.
23. Goldhirsch A, Morgan R, Yau J, et al: A phase II study of
DUP 937 in advanced breast cancer. Proc Am Soc Clin Oncol 11:76,
24. Hantel A, Donehower RC, Rowinsky EK, et al: Phase I study
and pharmacodynamics of piroxantrone (NSC-349174), a new anthrapyrazole.
Cancer Res 50:3284-3288, 1990.
25. Slichenmeyer WJ, Rowinsky EK, Donehower RC, et al: The current
status of camptothecin analogues as antitumor agents. J Natl Cancer
Inst 85:271-291, 1993.
26. Tanizawa A, Fujimori A, Fujimori Y, et al: Comparison of topoisomerase
I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives
presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994.
27. Chang AY, Garrow G, Boros L, et al: Clinical and laboratory
studies of topotecan in breast cancer. Proc Am Soc Clin Oncol
14:105, 1995. Abstract.
28. Bonneterre J, Pion JM, Adenis A, et al: A phase II study of
a new camptothecin analogue CPT-11 in previously treated advanced
breast cancer patients. Proc Am Soc Clin Oncol 12:94, 1993. Abstract.
29. Taguchi T: A novel anti-tumor agent, CPT-11 (a topoisomerase
I inhibitor). Ann Oncol 5(suppl 8):179, 1994. Abstract.
30. Buzdar AU, Hortobagyi GN, Esparza LT, et al: Elliptinium acetate
in metastatic breast cancer--a phase II study. Oncology 47:101-104,
31. Rouesse J, Spielmann M, Turpin F, et al: Phase II study of
elliptinium acetate salvage treatment of advanced breast cancer.
Eur J Cancer 29A:856-859, 1993.
32. Turpin F, Namer M, Spielmann M, et al: Phase II trial of datelliptium
chloride hydrochloride in metastatic breast cancer. Proc Am Assoc
Cancer Res 33:214, 1992. Abstract.
33. Takimoto CH, Allegra CJ: New antifolates in clinical development.
Oncology 9:649-659, 1995.
34. Bailey N, Laohavinij S, et al: A phase I study of 3 weekly
lometrexol (DDATHF) with folic acid supplementation (abstract
311). Ann Oncol 7:90, 1996
34a. Schornagel JH, van der Vegt S, Verweij J, et al: Phase II
study of edatrexate in chemotherapy-naive patients with metastatic
breast cancer. Ann Oncol 3:549-552, 1992.
35. Booser DJ, Dye CA, Clements SB, et al: Edatrexate (10-EDAM)
for metastatic breast cancer: Phase II study. Proc Am Soc Clin
Oncol 13:109, 1994. Abstract.
36. Vandenberg T, Pritchard KI, Eisenhauer E, et al: Phase II
study of weekly 10-EDAM (edatrexate) as first line chemotherapy
for metastatic breast cancer: A National Cancer Institute of Canada
Clinical Trials Group Study. Proc Am Soc Clin Oncol 11:51, 1992.
37. Perez EA, Whitall D, Hesketh PJ: Phase I trial of biweekly
edatrexate in metastatic breast cancer. Proc Am Soc Clin Oncol
13:59, 1994. Abstract.
38. Leiby JM: Trimetrexate: A phase 2 study in previously treated
patients with metastatic breast cancer. Semin Oncol 15(2; suppl
39. Dawson NA, Costanza ME, Korzun AH, et al: Trimetrexate in
untreated and previously treated patients with metastatic breast
cancer: A Cancer and Leukemia Group B Study. Med Pediatr Oncol
40. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine
(2',2'-difluorodeoxycytidine) in previously treated ovarian cancer
patients. J Natl Cancer Inst 86:1530-1533, 1994.
41. Catimel G, Vermorken JB, Clavel M, et al: A phase II study
of gemcitabine (LY 188011) in patients with advanced squamous
cell carcinoma of the head and neck. Ann Oncol 5:543-547, 1994.
42. Carmichael J, Possinger K, Philip P, et al: Difluorodeoxycytidine
(gemcitabine): A phase II study in patients with advanced breast
cancer. Proc Am Soc Clin Oncol 12:64, 1993. Abstract.
43. Uberall F, Oberhuber H, Maly K, et al: Hexadecylphosphocholine
inhibits inositol phosphate formation and protein kinase C activity.
Cancer Res 51:807-812, 1991.
44. ten Bokkel Huinink WW, Hilton A, Somers R: Topical application
of miltefosine against skin metastases of breast cancer. Ann Oncol
3(suppl 1):65, 1992. Abstract.
45. Unger C, Peukert M, Sindermann H, et al: Hexadecylphosphocholine
in the topical treatment of skin metastases in breast cancer patients.
Cancer Treat Rev 17:243-246, 1990.
46. Claassens K, ten Bokkel Huinink WW, Schornagel JH, et al:
Treatment of skin metastases of breast cancer by topical application
of miltefosine. Ann Oncol 3:86, 1992. Abstract.
47. Burk K, David M, Junge K, et al: Overview on the clinical
development of miltefosine solution (Miltex) for the treatment
of cutaneous breast cancer. Drugs Today 30:59-72, 1994.
48. Yau JC, Yap HY, Buzdar AU, et al: A comparative randomized
trial of vinca alkaloids in patients with metastatic breast carcinoma.
Cancer 55:337-340, 1985.
49. Burris III HA, Fields S: Summary of data from in vitro and
phase I vinorelbine (Navelbine) studies. Semin Oncol 21:14-20,
50. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial
of weekly intravenous vinorelbine in first-line advanced breast
cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993.
51. Garcia-Conde J, Lluch A, Martin M, et al: Phase II trial of
weekly IV Navelbine in first line advanced breast cancer chemotherapy.
Ann Oncol 5:854-857, 1994.
52. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study
of Navelbine in advanced breast cancer. Semin Oncol 16(suppl 4):33-36,
53. Weber B, Vogel C, Jones S, et al: A U.S. multicenter phase
II trial of Navelbine in advanced breast cancer. Proc Am Soc Clin
Oncol 12:61, 1993. Abstract.
54. Romero A, Rabinovich M, Vallejo C, et al: Promising preliminary
results of weekly Navelbine as first line chemotherapy for metastatic
breast cancer. Proc Am Soc Clin Oncol 12:76, 1993. Abstract.
55. Bruno S, Lira-Puerto V, Texeira L, et al: Phase II trial with
Navelbine in the treatment of advanced breast cancer patients.
Ann Oncol 3(suppl 1):126, 1992. Abstract.
56. Tresca P, Fumoleau P, Roche H, et al: Vinorelbine, a new active
drug in breast carcinoma: Results of an ARTAC phase II trial.
Breast Cancer Res Treat 16:123, 1990. Abstract.
57. Marty M, Leandri S, Extra JM, et al: A phase II study of vinorelbine
in patients with advanced breast cancer. Proc Am Assoc Cancer
Res 30:256, 1989. Abstract.
58. Henderson IC: Chemotherapy for metastatic disease. In: Harris
JR, Hellman S, Henderson IC, Kinne DW (eds). Breast Diseases,
2nd ed, pp 604-665. Philadelphia, JB Lippincott, 1991.
59. Jones S, Winer E, Vogel C, et al: A multicenter, randomized
trial of IV Navelbine vs. IV Alkeran in patients with anthracycline-refractory
advanced breast cancer. Proc Am Soc Clin Oncol 13:103, 1994. Abstract.
60. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med
61. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial
of two doses of Taxol in metastatic breast cancer: An interim
analysis. Proc Am Soc Clin Oncol 12:60, 1993. Abstract.
62. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory
or mitoxantrone-refractory breast cancer: A phase I/II trial of
96-hour infusion. J Clin Oncol 12:1621-1629, 1994.
63. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and
recombinant human granulocyte colony-stimulating factor as initial
chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951,
64. Davidson NG, Perren TJ, Chan S: Single-agent paclitaxel in
patients at first relapse following adjuvant chemotherapy for
breast cancer. The Breast 4:228-229, 1995. Abstract.
65. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic
breast cancer: A trial of two doses by a 3-hour infusion in patients
with disease recurrence after prior therapy with anthracyclines.
J Natl Cancer Inst 87:1169-1175, 1995.
66. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial
of Taxol, an active drug in the treatment of metastatic breast
cancer. J Natl Cancer Inst 83:1797-1805, 1991.
67. Holmes FA, Valero V, Walters RS, et al: The M.D. Anderson
Cancer Center experience with Taxol in metastatic breast cancer.
Monogr Natl Cancer Inst 15:161-169, 1993.
68. Pazdur R, Kudelka AP, Kavanagh JJ, et al: The taxoids: Paclitaxel
(Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386,
69. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second
and subsequent therapy for metastatic breast cancer: Activity
independent of prior anthracycline response. J Clin Oncol 13:1152-1159,
70. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel (Taxol) activity
in heavily treated metastatic breast cancer. Ann Oncol 5:199,
71. Seidman AD: The emerging role of paclitaxel in breast cancer
therapy. Clin Cancer Res 1:247-256, 1995.
72. Bissery M, Nohynek G, Sanderink G, et al: Docetaxel (Taxotere):
A review of preclinical and clinical experience. Part I: Preclinical
experience. Anticancer Drugs 6(3):339-355, 1995.
73. van Oosterom AT, Schrijvers D: Docetaxel (Taxotere), a review
of preclinical and clinical experience. Part II: Clinical experience.
Anticancer Drugs 6(3):356-368, 1995.
74. Fumoleau P, Chevallier B, Kerbrat P, et al: First line chemotherapy
with Taxotere in advanced breast cancer: A phase II study of the
EORTC clinical screening group. Proc Am Soc Clin Oncol 12:56,
75. Trudeau ME, Eisenhauer E, Lofters W, et al: Phase II study
of Taxotere as first line chemotherapy for metastatic breast cancer:
A National Cancer Institute of Canada Clinical Trials Group Study.
Proc Am Soc Clin Oncol 12:64, 1993. Abstract.
76. Seidman AD, Hudis C, Crown JPA, et al: Phase II evaluation
of Taxotere (RP56976, NSC 628503) as initial chemotherapy for
metastatic breast cancer. Proc Am Soc Clin Oncol 12:63, 1993.
77 ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase
II trial with docetaxel (Taxotere) in second line treatment with
chemotherapy for advanced breast cancer. Ann Oncol 5:527-532,
78. Valero V, Holmes FA, Walters RS, et al: Phase II trial of
docetaxel: A new highly effective antineoplastic agent in the
management of patients with anthracycline-resistant metastatic
breast cancer. J Clin Oncol 13(12):2886-2894, 1995.
79. Valero V, Walters RS, Theriault RL, et al: Phase II study
of docetaxel (Taxotere) in anthracycline-refractory metastatic
breast cancer. Proc Am Soc Clin Oncol 13:470, 1994. Abstract.
80. Ravdin P, Valero V, Burris III H, et al: Docetaxel (Taxotere)
therapy in anthracycline/anthracenedione or paclitaxel resistant
metastatic breast cancer. Proc Am Soc Clin Oncol 14:94, 1995.
81. Hortobagyi GN: Future directions for vinorelbine. Semin Oncol